Next-Generation Therapy for Inherited Blindness

Our People

Oak Bay Biosciences is a new biotechnology company – with a portfolio of patents, molecules, and preclinical data – with the goal to bring the first therapy for Stargardt disease to market. Stargardt disease affects approximately 800,000 individuals worldwide and causes progressive, irreversible blindness – often beginning in childhood. Oak Bay Biosciences' lead molecule could prevent blindness for the lifetime of a patient due to high potency, durability, and extended half-life in the eye.

Oak Bay Biosciences' business model is based on efficient and rapid progress to the clinic. We leverage over 100 years of biotech and start up experience across a lean virtual team and experienced Board of Directors.

David Kroeger, Ph.D.


Formerly, Director of R&D at Overa, Charlottesville VA

Formerly, Director of Lab Services, ImmunoPrecise Antibodies, Victoria BC

Immunooncology at BC Cancer Agency, Victoria BC



Matthew Levy, Ph.D.

Chief Scientific Advisor

CSO of Drive Therapeutics, Chapel Hill, NC

Formerly, Head of Discovery, Vitrisa Therapeutics, Raleigh-Durham, NC

Formerly, Associate Professor, Albert Einstein College of Medicine, Bronx, NY



Board Member


Chris Astle, CA, Ph.D.

Finance and Corporate Governance

CFO, The CFO Centre

Formerly, VP Finance, Alder Biopharmaceuticals Seattle, WA

Formerly, CFO-International Allergan, Marlow, UK



Board Chairman


Erich Mohr, Ph.D., ICD.D.

Translational Development

Chairman and CEO, MedGenesis Therapeutix Inc.

Formerly, CEO CroMedica Inc.

UVic board of Governors



Board Member


Paul Erickson, M.Sc.


Co-founder Axys Group, Victoria, BC

Formerly, CEO Seastar Chemicals, Victoria BC